

B S R & Co. LLP

Chartered Accountants


Building No.10, 8th Floor, Tower-B
DLF Cyber City, Phase - II
Gurgaon - 122 002, India


Telephone: + 91 124 2549 191
Fax: + 91 124 2549 101

Review Report to the Board of Directors of Jubilant Life Sciences Limited

1. We have reviewed the accompanying statement of un-audited standalone financial results ("the Statement") of Jubilant Life Sciences Limited ("the Company") for the quarter and half year ended 30 September 2013 attached herewith, being submitted by the Company pursuant to the requirements of Clause 41 of the Listing agreement issued by the Securities and Exchange Board of India ("Listing Agreement") except for the disclosures regarding "Public Shareholding" and "Promoter and Promoter Group Shareholding", which have been traced from the disclosures made by the management and have not been reviewed by us. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors on 29 October 2013. Our responsibility is to issue a report on this Statement, based on our review. The un-audited standalone financial results for the quarter ended 30 June 2013 included in the Statement were reviewed earlier by the then statutory auditors of the Company whose reports have been furnished to us and which have been relied upon by us for the purpose of our review of the Statement.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as explained in paras 1 and 2 above, nothing has come to our attention that causes us to believe that the accompanying un-audited standalone financial results, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**
Chartered Accountants
Firm registration number: 101248W


Kaushal Kishore
Partner
Membership No.: 090075

 Place: Gurgaon
Date: 29 October 2013

Jubilant Life Sciences Limited

Regd. Off: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)

Statement of Standalone Unaudited Results for the Quarter and Half year ended 30th September, 2013

(₹ in Lacs)

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30 September	30 June	30 September	30 September	30 September	31 March
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		2013	2013	2012	2013	2012	2013
	PART I						
1	Income from operations						
	(a) Net sales/Income from operations (Net of excise duty)	91691	81258	72912	172949	145793	309468
	(b) Other operating income	1076	1098	1225	2174	2601	5162
	Total income from operations (net)	92767	82356	74137	175123	148394	314630
2	Expenses						
	a) Cost of materials consumed	45436	41312	37471	86748	72906	152858
	b) Purchase of stock in trade	4026	4443	4944	8469	9671	19174
	c) Change in inventories of finished goods, work-in-progress and stock in trade	(1816)	(395)	(2950)	(2211)	(4668)	(2417)
	d) Power and fuel expense	9447	8599	8113	18046	16482	33791
	e) Employee benefits expense	7627	6646	6088	14273	11696	24865
	f) Depreciation and amortization expense	4391	4254	3686	8645	7293	15217
	g) Other expenses	10603	9776	8177	20379	16825	37797
	Total expenses	79714	74635	65529	154349	130205	281285
3	Profit/(Loss) from operations before other income, finance cost and exceptional items (1-2)	13053	7721	8608	20774	18189	33345
4	Other income	282	201	295	483	469	892
5	Profit/(Loss) from ordinary activities before finance costs and exceptional items (3+4)	13335	7922	8903	21257	18658	34237
6	Finance costs(Refer note 6 below)	6590	6403	5596	12993	11906	23029
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	6745	1519	3307	8264	6752	11208
8	Exceptional items (Refer note 7 Below)	14832	11684	(6234)	26516	3522	12489
9	Profit/(Loss) from ordinary activities before tax (7-8)	(8087)	(10165)	9541	(18252)	3230	(1281)
10	Tax expense (Net) (Refer note 8 below)	(229)	423	1181	194	2230	3051
11	Net Profit/(Loss) from ordinary activities after tax (9-10)	(7858)	(10588)	8360	(18446)	1000	(4332)
12	Extraordinary items (net of tax expenses)	-	-	-	-	-	-
13	Net Profit/(Loss) for the period (11-12)	(7858)	(10588)	8360	(18446)	1000	(4332)
14	Paid-up equity share capital (Face value per share ₹ 1)(Refer Note 4 below)	1593	1593	1593	1593	1593	1593
15	Reserves (excluding revaluation reserve)						182766
16	Earnings per share of ₹ 1 each before and after extraordinary items (Not annualized)						
	Basic (₹)	(4.93)	(6.65)	5.25	(11.58)	0.63	(2.72)
	Diluted (₹)	(4.93)	(6.65)	5.25	(11.58)	0.63	(2.72)
	PART II						
A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding						
	- Number of shares (₹ 1 each)	73355083	81166083	81166083	73355083	81166083	81166083
	- Percentage of shareholding	46.05	50.96	50.96	46.05	50.96	50.96
2	Promoters and promoter group Shareholding						
	a) Pledged/Encumbered						
	- Number of shares	-	-	3374000	-	3374000	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	4.32	-	4.32	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	2.12	-	2.12	-
	b) Non-Encumbered						
	- Number of shares	85926056	78115056	74741056	85926056	74741056	78115056
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	95.68	100.00	95.68	100.00
	- Percentage of shares (as a % of the total share capital of the company)	53.95	49.04	46.92	53.95	46.92	49.04
B	Investor Complaints						
	Pending at the beginning of the quarter		Nil				
	Received during the quarter		9				
	Disposed of during the quarter		9				
	Remaining unresolved at the end of the quarter		Nil				



2

Jubilant Life Sciences Limited

Note 1: Standalone Unaudited Segment wise Revenue, Results and Capital Employed for the Quarter and Half Year ended 30th September, 2013

Sr. No.	Particulars	Quarter Ended				Half Year Ended		Year Ended 31 March (Audited)	(₹ in Lacs)
		30 September		30 June		30 September			
		(Unaudited)		(Unaudited)		(Unaudited)			
		2013	2012	2013	2012	2013	2012		
1	Segment revenue								
	a. Pharmaceuticals	21535	19125	18717	40660	35958	75646		
	b. Life Sciences Ingredients	71299	63334	55488	134633	112572	239252		
	Total	92834	82459	74205	175293	148530	314898		
	Less : Inter segment revenue	67	103	68	170	136	268		
	Net Sales/Income from operations	92767	82356	74137	175123	148394	314630		
	a. Pharmaceuticals	21535	19125	18717	40660	35958	75646		
	b. Life Sciences Ingredients	71232	63231	55420	134463	112436	238984		
	Total	92767	82356	74137	175123	148394	314630		
2	Segment results (profit(+)/loss(-) before tax and interest from each segment)								
	a. Pharmaceuticals	6597	3549	4044	10146	7669	15133		
	b. Life Sciences Ingredients	9473	6379	6357	15852	14201	27370		
	Total	16070	9928	10401	25998	21870	42503		
	Less : i Interest (Finance costs)	6590	6403	5596	12993	11906	23029		
	ii. Other un-allocable expenditure (including exceptional items)	17849	13891	(4441)	31740	7203	21647		
	iii. Un-allocable Income	(282)	(201)	(295)	(483)	(469)	(892)		
	Total Profit/(Loss) before tax	(8087)	(10165)	9541	(18252)	3230	(1281)		
3	Capital Employed (Segment assets less Segment liabilities)								
	a. Pharmaceuticals	109809	102190	98637	109809	98637	98684		
	b. Life Sciences Ingredients	162211	149717	165136	162211	165136	128987		
	Total capital employed in segments	272020	251907	263773	272020	263773	227671		
	Add: Un-allocable corporate assets less liabilities	216081	226012	267460	216081	267460	263705		
	Total capital employed in the Company	488101	477919	531233	488101	531233	491376		

Jubilant Life Sciences Limited
Regd. Off: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)

Note 2: Statement of Standalone Assets And Liabilities

(₹ in Lacs)

Particulars	As at 30 September (Un-audited) 2013	As at 31 March (Audited) 2013
EQUITY AND LIABILITIES		
Shareholders' Funds		
a) Share capital (Refer note 4)	1545	1593
b) Reserves and surplus (Refer note 4 & 5)	145074	182766
c) Money received against share warrants	-	-
Sub-total- Shareholders' funds	146619	184359
Share application money pending allotment	-	-
Minority interest	-	-
Non-current liabilities		
a) Long-term borrowings	143336	200838
b) Deferred tax liabilities(Net)	21241	26016
c) Other long term liabilities	-	-
d) Long-term provisions	37010	22735
Sub-total- Non-current liabilities	201587	249589
Current liabilities		
a) Short-term borrowings	93996	63256
b) Trade payables	85445	93477
c) Other current liabilities	101162	47129
d) Short-term provisions	20206	11360
Sub-total- Current liabilities	30809	215222
TOTAL EQUITY AND LIABILITIES	649015	649170
ASSETS		
Non-current assets		
a) Fixed assets	242923	239884
b) Goodwill on consolidation	-	-
c) Non-current investments	197929	197851
d) Deferred tax assets(net)	-	-
e) Long-term loans and advances	44927	49522
f) Other non-current assets	10	22
Sub-total- Non-current assets	485789	487279
Current assets		
a) Current investments	-	-
b) Inventories	74441	61121
c) Trade receivables	54120	39325
d) Cash and bank balances	4823	25588
e) Short-term loans and advances	29193	29926
f) Other current assets	649	5931
Sub-total- Current assets	163226	161891
TOTAL ASSETS	649015	649170



Notes:

3. In line with its earlier decision of consolidation of Pharmaceuticals business under its wholly owned subsidiary Jubilant Pharma Limited Singapore (JPL) and evaluate the option and opportunity to raise money to reduce the consolidated debt of the Company, the Board in its meeting held on 4 October 2013 approved transfer of Active Pharmaceutical Ingredients (API) and Dosage Forms business of the Company by way of a slump sale on going concern basis and shares held by it in Jubilant Pharma Holding Inc USA and Jubilant Pharma NV Belgium, to a wholly owned Indian subsidiary of JPL for a net consideration of ₹ 114510 lacs (net of debts), subject to Shareholders' and other regulatory approvals. JPL has received an approval from the Foreign Investment Promotion Board in this regard.

4. During the quarter, the Company has consolidated the accounts of the Jubilant Employee Welfare Trust (Trust) with the Company. The Trust primarily holds equity shares of the Company which are to be transferred to employees of the Company and its subsidiaries upon exercise of their stock options under various Employee Stock Option Plans (ESOP) in force. Consequently, the face value of 4833496 equity shares held by trust as at 30 September 2013 amounting to ₹ 48 lacs, is reduced from the share capital and the excess of net worth (after elimination of inter-company loans) of ₹ 4200 lacs has been adjusted from reserves and surplus. The aforesaid adjustment did not have any effect on the financial results of the Group for the quarter and half year ended 30 September 2013.

5. The Company has applied hedge accounting in respect of certain foreign currency transactions including forward contracts under Accounting Standard 30 and the debit/ (credit) balance in Hedging Reserve (net) representing a portion of foreign exchange loss/ gain on such transactions (after adjustment for related tax impact) as at 30 September 2013 and 31 March 2013 is ₹ 6109 lacs (debit balance) and ₹ 3541 lacs respectively.

6. Finance cost includes exchange difference arising from foreign currency short-term borrowings regarded as an adjustment to interest costs as per AS 16-Borrowing Costs, and is gross of credit on the swap contracts as under:

Particulars	Quarter Ended			Half Year Ended		(₹ in Lacs)
						Year Ended
	30 September	30 June	30 September	30 September	30 September	31 March
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	2013	2013	2012	2013	2012	2013
- Finance Cost net of credit on swap contracts	4977	4821	4323	9798	8828	17117
Add : Foreign Exchange differences and credit on swap contracts	1613	1582	1273	3195	3078	5912
- Gross Finance Cost	6590	6403	5596	12993	11906	23029

7. Exceptional items for each period presented includes:

i) Amortization of debit balance in Foreign Currency Monetary Items Translation Difference Account (FCMITDA) of ₹ 3874 lacs, ₹ 2551 lacs, ₹ 637 lacs, ₹ 6425 lacs, ₹ 2315 lacs and ₹ 6316 lacs for the quarters ended 30 September 2013, 30 June 2013, 30 September 2012; half year ended 30 September 2013, 30 September 2012; and year ended 31 March 2013 respectively, representing exchange difference on long-term foreign currency monetary liability which has been used for the purpose other than acquiring fixed assets.

ii) The remaining amount of exceptional items for all periods presented primarily represents foreign exchange difference for the period (excluding portion included in finance cost) and mark to market gain/ loss (net of related contractual recoveries) in respect of currency and interest rate swap contracts.

8. Tax expense for the quarter and six months ended 30 September 2013 is net of creation of deferred tax asset and true up of current tax amounting to (₹ 194) lacs in relation to reassessment of tax positions of earlier periods.

9. The Ministry of Commerce, Republic of China had imposed 24.6 % antidumping duty on pyridine imported from the company for domestic sale in China, for which final order is still awaited and the impact of the same is charged in financial results.

10. Previous periods figures have been reclassified to conform to the current period's classification.

11. The above un-audited results were, subjected to limited review by the Statutory Auditors of the Company, reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 29 October 2013. The review report of the Statutory Auditors is being filed with the Bombay Stock Exchange and National Stock Exchange and is also available on the Company's website at www.jubl.com.

For Jubilant Life Sciences Limited


Shyam S Bhartia
Chairman & Managing Director

Place : Noida

Date : 29th October, 2013

